Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
| Revenue (TTM) | $1.22B |
| Gross Profit (TTM) | $668.51M |
| EBITDA | $576.58M |
| Operating Margin | 38.00% |
| Return on Equity | 27.80% |
| Return on Assets | 8.60% |
| Revenue/Share (TTM) | $4.27 |
| Book Value | $2.33 |
| Price-to-Book | 8.10 |
| Price-to-Sales (TTM) | 4.41 |
| EV/Revenue | 6.0 |
| EV/EBITDA | 13.71 |
| Quarterly Earnings Growth (YoY) | 570.00% |
| Quarterly Revenue Growth (YoY) | 9.20% |
| Shares Outstanding | $285.38M |
| Float | $184.78M |
| % Insiders | 2.31% |
| % Institutions | 107.04% |
Volatility is currently contracting
Sotera Health NASDAQ: SHC reported second-quarter 2026 results that included 8% constant-currency revenue growth, higher adjusted EBITDA margins and an increase to its full-year revenue and adjusted EBITDA outlook.
Sotera Health Company (SHC) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sotera Health Company (SHC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.2 per share a year ago.
Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis (1) compared to Q2 2025 Q2 2026 net income of $54 million or $0.19 per diluted share, compared to net income of $8 million or $0.03 per diluted share in Q2 2025 Q2 2026 Adjusted EBITDA ( 1 ) increased 10.0%, or 8.7% on a constant currency basis Q2 2026 Adjusted EPS (1) of $0.26, an increase of 30% per diluted share Company raises both full-year 2026 net revenues growth out look to 5.25% - 6.75% and Adjusted EBITDA growth outlook to 5.75% - 7.25%, on a constant currency basis CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and six- months ended June 30, 2026. “We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units,” said Chief Executive Officer Alton Shader.
CLEVELAND, July 23, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2026 before the market opens on Thursday, August 6, 2026. Following the release, management will host a conference call at 9:00 a.m.
Sotera Health Company (SHC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 31,838,253 shares of its common stock, par value $0.01 per share. All 31,838,253 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders.
Sotera Health Company (SHC) Q1 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Sotera Health (SHC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SHC and any ticker you trade — then tracks every position and per-strategy win rate.
